Share This Page
Drug Price Trends for NDC 54092-0519
✉ Email this page to a colleague
Average Pharmacy Cost for 54092-0519
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INTUNIV ER 4 MG TABLET | 54092-0519-02 | 9.29900 | EACH | 2025-12-17 |
| INTUNIV ER 4 MG TABLET | 54092-0519-02 | 9.28707 | EACH | 2025-11-19 |
| INTUNIV ER 4 MG TABLET | 54092-0519-02 | 9.29076 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 54092-0519
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 54092-0519
Introduction
NDC 54092-0519 refers to a specific pharmaceutical product classified under the National Drug Code (NDC) system maintained by the US Food and Drug Administration (FDA). Analyzing its market landscape and price trajectory involves understanding its therapeutic class, competitive environment, regulatory status, and current financial trends.
This comprehensive assessment aims to inform stakeholders—including investors, healthcare providers, and pharmaceutical companies—regarding the drug’s market position, growth potential, and pricing strategies.
Product Overview
While the NDC code identifies the drug’s manufacturer and formulation, detailed information such as active ingredients, therapeutic indication, and formulation specifics are essential for accurate market assessment. Based on publicly available data, NDC 54092-0519 is linked to [Insert drug name, e.g., a biologic or small-molecule medication], indicated for [primary indication, e.g., rheumatoid arthritis, diabetes, oncology, etc.].
The drug’s approval status by the FDA and subsequent regulatory actions influence its market dynamics. As of the latest data, this product holds [market authorization status, e.g., FDA-approved, under supplemental application, or in clinical trials].
Market Landscape
Therapeutic Area & Market Size
The drug operates within the [specific therapeutic category, e.g., immunology, oncology, neurology] space, which has witnessed increased demand driven by [e.g., rising prevalence rates, innovation in biologics, unmet medical needs]. The segment has shown robust growth, with estimates projecting a compounded annual growth rate (CAGR) of [X]% over the next five years (source: [industry report, IQVIA, Statista]).
Competitive Environment
The competitive landscape features [number] key players producing comparable therapeutics. Major competitors include [list of primary competitors and their products], which offer similar efficacy and safety profiles. The introduction of biosimilars or generics has intensified price competition, exerting downward pressure on brand-name prices.
The market's evolution is also shaped by [patent expirations, regulatory exclusivities, innovative delivery methods, or combination therapies]. For example, if patent exclusivity expires in [year], the market could see a surge in generic or biosimilar entrants, often leading to price erosion.
Regulatory and Reimbursement Factors
Pricing strategies are heavily influenced by [Medicare, Medicaid, private insurance reimbursement policies, and value-based pricing agreements]. Favorable reimbursement terms can bolster market share, while reimbursement hurdles or stringent prior authorization processes may restrict access and pricing flexibility.
Recent policies favoring biosimilars to reduce treatment costs could significantly affect NDC 54092-0519’s market share if biosimilars gain regulatory approval. In addition, utilization management strategies, including specialty pharmacy distribution, impact market penetration and pricing.
Current Pricing Dynamics
Historical Pricing Trends
As of 2023, the average wholesale price (AWP) for drugs like NDC 54092-0519 ranges between $X and $Y, with variations based on dosage, supply chain negotiations, and regional factors. Price adjustments often correlate with patent status changes or shifts in manufacturing costs.
Pricing Drivers
- Regulatory exclusivity and patent protections sustain higher list prices.
- Manufacturing costs influence floor prices, especially for biologics requiring complex production.
- Market competition, especially from generics or biosimilars, exerts downward pressure.
- Reimbursement policies and payer negotiations shape actual transaction prices.
Pricing Challenges
The ongoing biosimilar landscape fosters aggressive pricing strategies, leading to a potential drop of [X]% in net product prices upon biosimilar entry. Additionally, pricing for specialty drugs like NDC 54092-0519 often faces scrutiny due to policy debates on affordability.
Price Projection Analysis
Short-Term Outlook (Next 1-2 Years)
In the near term, assuming no patent expiry or biosimilar entry, price stability or slight increases are expected due to:
- Rising demand for effective treatment options.
- Incremental value-based pricing adjustments.
- Contract negotiations favoring the manufacturer.
However, market pressures from payers enforcing stricter formulary controls may cap price hikes at 2-3% annually.
Medium-to-Long-Term Trends (3-5 Years)
Post-patent expiry or if biosimilars gain approval and market share, prices could decline substantially—by 30-50% or more. Historical data from similar biologic products suggests:
- Biosimilar introductions generally lead to 15-30% reductions in average selling prices within 2 years.
- Price erosion accelerates if multiple biosimilar competitors enter simultaneously.
Furthermore, technological innovations, such as personalized medicine or combination therapies, could temporarily sustain or elevate prices by expanding therapeutic indications or improving clinical outcomes.
Strategic Implications for Stakeholders
- Manufacturers should anticipate biosimilar competition and early-stage price reductions; investing in value-added services and patient support programs could mitigate erosion.
- Payers are increasingly leveraging formulary management and prior authorization, exerting downward pressure on prices.
- Investors should monitor pipeline developments, patent litigation outcomes, and regulatory approvals that influence market exclusivity, affecting price trajectories.
Key Takeaways
- NDC 54092-0519 operates within a dynamic, competitive therapeutic area with growing demand.
- Current pricing is influenced heavily by patent protection, market competition, and reimbursement policies.
- Short-term prices are expected to remain stable or rise modestly, while significant declines are probable post-biosimilar entry.
- Market entry of biosimilars and regulatory changes are primary catalysts for future price reductions.
- Strategic positioning, including early adoption of value-based pricing and diversification, is vital amid increasing biosimilar competition.
FAQs
1. What is the primary therapeutic indication for NDC 54092-0519?
It is indicated for [insert primary indication], targeting patients with [specific condition], addressing unmet needs in [specific patient population].
2. How does patent expiration influence the pricing of this drug?
Patent expiration typically exposes the drug to biosimilar or generic competition, leading to significant price reductions—often 30-50%—to remain competitive.
3. What are the key factors affecting reimbursement and net pricing?
Reimbursement depends on insurer policies, formulary placement, clinical value, and negotiations. Payer pressure and legislative policies increasingly favor lower-cost options.
4. How might biosimilar entry impact the market for this drug?
Biosimilars introduce lower-cost alternatives, exerting pricing pressure, reducing market share of the original biologic, and potentially improving patient access.
5. What strategic steps can manufacturers take to maximize revenue from NDC 54092-0519?
Strategies include extending regulatory exclusivity, enhancing clinical value, engaging in value-based pricing, and investing in patient support programs to strengthen market presence.
References
- IQVIA Institute for Human Data Science, “Global Oncology Market Report,” 2022.
- U.S. Food & Drug Administration, “Biologics Price Competition and Innovation Act” (BPCIA), 2010.
- CMS.gov, “Part D and Part B Medicare Reimbursement Policies,” 2022.
- EvaluatePharma, “Biologic & Biosimilar Price Trends,” 2022.
- MarketWatch, “Pharmaceutical Price Trends and Outlook,” 2023.
Note: Specific drug name, indications, and precise pricing data should be incorporated as per the latest available information for an authoritative report.
More… ↓
